hyaluronidase (ovine) (Vitrase) Report issue

Animal product Approved FDA Priority Review FDA
AACT ChEMBL

Active Ingredient History

NOW
  • Now
Hyaluronidases are a family of enzymes that catalyse the degradation of hyaluronic acid (HA). Karl Meyer classified these enzymes in 1971, into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$72.3750 - $87.9650
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

hyaluronidase | ovine hyaluronidase | vitrase

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Dry Eye Syndromes (approved 2004)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Diabetic Retinopathy (Phase 3)

Drug Hypersensitivity (Phase 1)

Pain (Phase 4)

Vitreous Detachment (Phase 2)

Vitreous Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue